PREVIOUS TRANSACTIONS. During the twelve months period immediately prior to entering into the New Agreements, the Group had entered into the Previous Transactions with the Customer which consist of:
PREVIOUS TRANSACTIONS. Prior to this Agreement, each Buyer has purchased or otherwise obtained securities issued by the Company.
PREVIOUS TRANSACTIONS. During the twelve-month period immediately prior to entering into the Commercial Factoring Agreement, the Group had entered into the Previous Transactions with the Customer which consisted of:
PREVIOUS TRANSACTIONS. During the twelve months period immediately prior to entering into the Entrusted Loan Agreement, the Group had entered into the Previous Transactions with the Customer which consist of:
PREVIOUS TRANSACTIONS. As a result of past transactions, a hybrid debt instrument or convertible debt (the “ORA”) in the initial principal amount of €45 million was issued by Auxitrol Technologies, S.A. (“Auxitrol Tech”) to ETD. ETD transferred the ORA to Esterline as partial payment of an inter-company loan from Esterline to ETD. The obligations of Auxitrol Tech were assumed by Auxitrol S.A. by operation of law when Auxitrol Tech was merged into Auxitrol S.A. on February 23, 2007. On August 9, 2007, Esterline sold the interest receivable in the ORA to ETD in exchange for a note payable to Esterline. ETD converted interest receivable on the ORA into capital through a share capital increase in Auxitrol S.A. As described in Part I, Step 2described in Section 1.2 above, ETD is to be dissolved in 2011 and the assets of ETD will be distributed to Esterline. Required Lender consent is requested for these past steps.
PREVIOUS TRANSACTIONS. All previous transactions completed by the Company have been fully disclosed to the Underwriters, were completed in compliance with all applicable laws and all necessary corporate, third party and regulatory approvals, consents, authorizations, registrations and filings required in connection therewith were obtained or made, as applicable, and complied with in all material respect;
PREVIOUS TRANSACTIONS. All previous transactions completed by the Corporation and which are material to the Corporation have been fully disclosed to the Agents, were completed in material compliance with all Applicable Laws and all necessary corporate and regulatory approvals, consents, authorizations, registrations, and filings required in connection therewith were obtained or made, as applicable, and complied with in all material respects.
PREVIOUS TRANSACTIONS. During the twelve-month period immediately prior to entering into the Factoring Financing Amendment and Extension Agreement II, the Group had entered into the Previous Transactions with the Customer which consisted of:
PREVIOUS TRANSACTIONS. In accordance with the PRC laws including the listing rules of the Shanghai Stock Exchange, save for (i) the transactions entered into by the Company with the TPH Group (comprising TPH, its subsidiaries and associated companies) relating to labour services and house leasing with an aggregate value of RMB37,822,400, representing approximately 0.58% of the Company’s latest audited net assets attributable to its parent company, (ii) the subscription of shares in NewScen Coast Bio-Pharmaceutical Co., Ltd. ( 天津中新科炬生物制药股份有限公司), a controlled subsidiary (as determined in accordance with the laws of the PRC) of the Company and a joint investment2 with TPH, with an aggregate value of RMB52,800,000, representing approximately 0.81% of the Company’s latest audited net assets attributable to its parent company, (iii) the acquisition of 15% equity interest in Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药 集团财务有限公司) 3 through a public bidding ( 公开摘牌) process at a consideration of RMB87,823,860, representing approximately 1.35% of the Company’s latest audited net assets attributable to its parent company, and (iv) the proposed entry into the two (2) Construction 2 As at the date of this announcement, TPH and the Company respectively holds 1.94% and 64.09% of the total shareholding in NewScen Coast Bio-Pharmaceutical Co., Ltd. (天津中新科炬生物制药股份有限公司). 3 As at the date of this announcement, TPH and the Company respectively holds 50% and 30% of the total shareholding in in Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司). Contracts for Tianjin Small Construction Project (天津市小型建设工程施工合同) with Tianjin Pharmaceutical Design Institute Co., Ltd. (天津市医药设计院有限公司) of an aggregate contract value of RMB6,764,311, representing approximately 0.10% of the Company’s latest audited net assets attributable to its parent company, there were no other related party transactions (excluding transactions conducted under the general shareholders’ mandate) over the past twelve (12) months up to the date of this announcement. By Order of the Board Xxxx Xxx
PREVIOUS TRANSACTIONS. Transactions entered into prior to the effective date of a Master Agreement will be subject to such Master Agreement, individually or by category, to the extent provided in the Special Provisions.
